Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

GLUE vs DMAC: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DMAC Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 4–6 Matrix Metrics)

DMAC Overall Winner 6-Pillar Tally: GLUE 2 – 3 DMAC (1 Tie) Matrix Metrics: GLUE 6 – 4 DMAC

As of Nov 16, 2026, DiaMedica Therapeutics Inc. (DMAC) is the stronger overall head-to-head candidate over Monte Rosa Therapeutics, Inc. (GLUE) in the Tradestie Institutional Equity Comparison Engine, winning 4–6 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). GLUE carries a Unified Composite Score of 44.2/100 (HOLD) at $9.11 (10.0x Forward P/E, -214.5% operating margin), whereas DMAC carries 46.3/100 (HOLD) at $8.41 (N/M Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: DMAC earns the overall head-to-head edge with a stronger Unified Composite Score (46.3/100 HOLD vs. GLUE 44.2/100 HOLD) and 1.74β · 98% Vol risk profile, whereas GLUE leads top-line expansion (+325.8% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: GLUE is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.3); meanwhile DMAC trades in a Neutral technical trend (SURGE options phase, RSI 44.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About GLUE vs DMAC
GLUE NASDAQ
Monte Rosa Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$9.11
-2.77% 1D
Market Cap $795.5M
TTM Revenue $70M
Forward P/E 10.0x
Beta / 30D Vol 0.94β · 53% Vol
Unified Composite Score
44.2 / 100 HOLD
Tech 32.0 Fund 51.0 Flow 70.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -13.2%), weak momentum, RSI 31
RSI-14: 31.3 · SMA20: $10.50 · SMA50: $11.21
DMAC NASDAQ Head-to-Head Winner
DiaMedica Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$8.41
-4.27% 1D
Market Cap $503.1M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.74β · 98% Vol
Unified Composite Score
46.3 / 100 HOLD
Tech 30.0 Fund 51.0 Flow 65.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 45
RSI-14: 44.7 · SMA20: $9.24 · SMA50: $8.24

6-Pillar Scorecard Institutional Category Breakdown (GLUE 2 – 3 DMAC)

Columns: Metric · GLUE · DMAC
1. Valuation Multiples GLUE
Forward P/E 10.0x N/M
Trailing P/E 10.0x N/M
PEG Ratio N/M N/M
EV / Revenue 11.2x N/M
2. Growth & Scale GLUE
Revenue Growth (YoY) +325.8% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $70M N/A
Market Cap $795.5M $503.1M
3. Profitability & Quality DMAC
Gross Margin -92.2% N/A
Operating Margin -214.5% 0.0%
Net Profit Margin -186.2% 0.0%
Return on Equity (ROE) -35.3% -114.6%
4. Balance Sheet & Cash Flow DMAC
Cash Generation (TTM) -$174M -$32M
Cash Flow Margin N/A N/A
Net Cash / Leverage $8.9M Net Cash $4.9M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning DMAC
Options Structure Phase BREAKDOWN SURGE
Current IV / %ile 100.8% (16th %ile) 106.3% (14th %ile)
Put/Call OI Skew 6.27x (Put-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: GLUE (6) vs DMAC (4)
Institutional Metric GLUE DMAC Criterion Row Edge
Market Capitalization
Scale
$795.5M $503.1M Larger Scale GLUE
Trailing P/E Ratio
Valuation
10.0x N/M Lower Multiple GLUE
Forward P/E Ratio
Valuation
10.0x N/M Lower Multiple GLUE
Revenue Growth (YoY)
Growth
+325.8% +0.0% Higher Growth GLUE
Operating Margin (TTM)
Profitability
-214.5% 0.0% Higher Margin DMAC
Net Profit Margin
Profitability
-186.2% 0.0% Higher Margin DMAC
Return on Equity (ROE)
Capital Efficiency
-35.3% -114.6% Higher ROE GLUE
52-Week Range Position
Momentum
1% ($9–$26) 55% ($5–$11) Stronger Trend DMAC
Beta / 30D Volatility
Risk Regime
0.94β · 53% Vol 1.74β · 98% Vol Lower Realized Risk GLUE
Unified Institutional Score
Composite Signal
44.2 / 100 (HOLD) 46.3 / 100 (HOLD) Higher Composite DMAC
Trailing 12M Revenue (USD)
Operating Scale
$70M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-92.2% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 11.2x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$174M ($8.9M Net Cash) -$32M ($4.9M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon DMAC +17.63 pp
GLUE: -6.47% · DMAC: +11.16%
3M Horizon DMAC +66.7 pp
GLUE: -39.39% · DMAC: +27.31%
6M Horizon DMAC +97.57 pp
GLUE: -49.42% · DMAC: +48.15%
1Y Horizon DMAC +91.64 pp
GLUE: -36.38% · DMAC: +55.26%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period GLUE Revenue DMAC Revenue GLUE Op. Margin DMAC Op. Margin Margin Leader
FY2018 N/A $0M N/A -1352.2% DMAC
FY2024 $80M N/A -107.3% N/A GLUE
FY2025 $120M N/A -43.8% N/A GLUE

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
GLUE BREAKDOWN
85d in phase · OBV DISTRIBUTION
Current IV 100.8%
IV Percentile 16th %ile
Put/Call OI Skew 6.27x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact GLUE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
DMAC SURGE
8d in phase · OBV NEUTRAL
Current IV 106.3%
IV Percentile 14th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact DMAC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
GLUE Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $795.5M market capitalization and -214.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
DMAC Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $503.1M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ GLUE vs DMAC Key Questions & Quantitative Answers

As of Nov 16, 2026, DiaMedica Therapeutics Inc. (DMAC) is the stronger overall head-to-head candidate over Monte Rosa Therapeutics, Inc. (GLUE) in the Tradestie Institutional Equity Comparison Engine, winning 4–6 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). GLUE carries a Unified Composite Score of 44.2/100 (HOLD) at $9.11 (10.0x Forward P/E, -214.5% operating margin), whereas DMAC carries 46.3/100 (HOLD) at $8.41 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: DMAC earns the overall head-to-head edge with a stronger Unified Composite Score (46.3/100 HOLD vs. GLUE 44.2/100 HOLD) and 1.74β · 98% Vol risk profile, whereas GLUE leads top-line expansion (+325.8% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: GLUE is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.3); meanwhile DMAC trades in a Neutral technical trend (SURGE options phase, RSI 44.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

GLUE leads the Growth & Scale pillar: GLUE posts +325.8% YoY revenue growth and +0.0% YoY earnings growth on $70M TTM revenue (-92.2% gross margin, -214.5% operating margin), compared with DMAC at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 3-period historical trajectory (FY2018 to FY2025), GLUE cumulative revenue shifted +50.0% while DMAC shifted N/A. In operating R&D and SG&A reinvestment, GLUE deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DMAC.

GLUE screens cheaper on headline valuation multiples. GLUE trades at 10.0x Forward P/E, 10.0x Trailing P/E, N/M PEG, and 11.2x EV/Revenue (unreported FCF margin), whereas DMAC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against GLUE (-35.3% ROE) versus DMAC (-114.6% ROE) capital efficiency.

In options market volatility and institutional positioning, GLUE carries 100.8% implied volatility (16th %ile, Compressed (<25th %ile)), a 6.27x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.94β · 53% Vol realized risk). By comparison, DMAC carries 106.3% implied volatility (14th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (1.74β · 98% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.